Anne Schett1, Sacha I Rothschild2, Alessandra Curioni-Fontecedro3, Stephan Krähenbühl4, Martin Früh5,6, S Schmid5, Christoph Driessen5, Markus Joerger7,8. 1. University of Basel, Basel, Switzerland. 2. Department of Medical Oncology, University Hospital, Basel, Switzerland. 3. Department of Medical Oncology and Hematology, University Hospital, Zurich, Switzerland. 4. Division of Clinical Pharmacology& Toxicology, University Hospital, Basel, Switzerland. 5. Department of Medical Oncology, Cantonal Hospital, Rorschacherstr. 95, 9007, St. Gallen, Switzerland. 6. University of Bern, Bern, Switzerland. 7. University of Basel, Basel, Switzerland. markus.joerger@kssg.ch. 8. Department of Medical Oncology, Cantonal Hospital, Rorschacherstr. 95, 9007, St. Gallen, Switzerland. markus.joerger@kssg.ch.
Abstract
PURPOSE: In this study, we test the hypothesis that the use of ATB reduces the efficacy of PD(L)1-targeting mAb. METHODS: We included patients with locally advanced, inoperable or metastatic, EGFR wildtype and ALK-negative non-small-cell lung cancer (NSCLC) who received a PD(L)1 targeting mAb (immune checkpoint inhibitor, ICI) between January 2013 and December 2017. The primary study objective was to assess the predictive impact of ATB use within 2 months prior to starting ICI treatment on overall survival from the time of starting ICI treatment (OS-ICI). RESULTS: 33 out of 218 evaluable patients (15.1%) received ATB within 2 months prior to starting ICI treatment. The use of ATB prior to starting ICI was associated with a lower rate of radiological response (18.2 vs. 28.3%, respectively, P = 0.02). PFS was significantly shorter in patients receiving ATB within 2 months prior to ICI compared to those not receiving ATB (median PFS 1.4 vs. 5.5 months, HR = 2.22, P < 0.01). OS-ICI was significantly shorter in NSCLC patients receiving ATB within 2 months prior to ICI compared to those not receiving ATB (median OS-ICI 1.8 vs. 15.4 months, HR = 2.61, P < 0.01; adjusted HR = 3.73, P < 0.01). CONCLUSION: The results of this study suggest that ATB may have a deleterious effect in patients with advanced NSCLC receiving ICI treatment, and more research seems to be justified to explore potential mechanisms.
PURPOSE: In this study, we test the hypothesis that the use of ATB reduces the efficacy of PD(L)1-targeting mAb. METHODS: We included patients with locally advanced, inoperable or metastatic, EGFR wildtype and ALK-negative non-small-cell lung cancer (NSCLC) who received a PD(L)1 targeting mAb (immune checkpoint inhibitor, ICI) between January 2013 and December 2017. The primary study objective was to assess the predictive impact of ATB use within 2 months prior to starting ICI treatment on overall survival from the time of starting ICI treatment (OS-ICI). RESULTS: 33 out of 218 evaluable patients (15.1%) received ATB within 2 months prior to starting ICI treatment. The use of ATB prior to starting ICI was associated with a lower rate of radiological response (18.2 vs. 28.3%, respectively, P = 0.02). PFS was significantly shorter in patients receiving ATB within 2 months prior to ICI compared to those not receiving ATB (median PFS 1.4 vs. 5.5 months, HR = 2.22, P < 0.01). OS-ICI was significantly shorter in NSCLC patients receiving ATB within 2 months prior to ICI compared to those not receiving ATB (median OS-ICI 1.8 vs. 15.4 months, HR = 2.61, P < 0.01; adjusted HR = 3.73, P < 0.01). CONCLUSION: The results of this study suggest that ATB may have a deleterious effect in patients with advanced NSCLC receiving ICI treatment, and more research seems to be justified to explore potential mechanisms.
Entities:
Keywords:
Antibiotics; Checkpoint inhibitors; Gut microbiota; Immunotherapy; Lung cancer
Authors: Amit A Kulkarni; Maryam Ebadi; Shijia Zhang; Mohamad A Meybodi; Alaa M Ali; Todd DeFor; Ryan Shanley; Daniel Weisdorf; Charles Ryan; Sumithira Vasu; Armin Rashidi; Manish Ramesh Patel Journal: ESMO Open Date: 2020-09
Authors: Maximilian Boesch; Florent Baty; Werner C Albrich; Lukas Flatz; Regulo Rodriguez; Sacha I Rothschild; Markus Joerger; Martin Früh; Martin H Brutsche Journal: Oncoimmunology Date: 2021-12-10 Impact factor: 8.110
Authors: Maximilian Boesch; Florent Baty; Sacha I Rothschild; Michael Tamm; Markus Joerger; Martin Früh; Martin H Brutsche Journal: Br J Cancer Date: 2021-04-06 Impact factor: 7.640